### Guidelines comparison table on the pharmacological management of type 2 diabetes mellitus (adults)

<table>
<thead>
<tr>
<th>Condition</th>
<th>ADDED</th>
<th>DPP-4i</th>
<th>GLP-1 RA</th>
<th>ISR</th>
<th>SGLT-2i</th>
<th>DUAL</th>
<th>TRIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Moderate</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>High</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

**Notes:**
- **Sulfonylurea**: Low and moderate doses can be added to higher doses of metformin.
- **DPP-4i**: Low or moderate doses are generally recommended.
- **GLP-1 RA**: Dose adjustments may be needed based on response.
- **ISR**: ISR is recommended based on the individual's condition.
- **SGLT-2i**: Dose adjustments may be needed based on response.

**ABBREVIATIONS**
- CVOT: Cardiovascular outcome trial
- DPP-4i: Dipeptidyl peptidase 4 inhibitor
- eGFR: Estimated glomerular filtration rate
- ESRD: End-stage renal disease
- GLP-1 RA: Glucagon-like peptide-1 receptor agonist
- NICE: National Institute for Health and Care Excellence
- SIGN: Scottish Intercollegiate Guidelines Network

**References:**
- Dapagliflozin has primary heart failure outcome data from DAPA-HF.
- Degludec or U100 glargine have demonstrated CVD safety.
- K Consider basal insulin with lower risk of hypoglycaemia: degludec/glargine U300 < glargine U100/detemir < NPH insulin.
- K Consider basal insulin with lower risk of hypoglycaemia: degludec/glargine U300 < glargine U100/detemir < NPH insulin.
- K Consider basal insulin with lower risk of hypoglycaemia: degludec/glargine U300 < glargine U100/detemir < NPH insulin.